

Chapter VIII

References

References:

- A desktop guide to Type 2 diabetes mellitus.** European Diabetes Policy Group (1999) Diabet Med.16(9), 716-730.
- Abbreviated Report of a WHO Consultation (2001)** Use of Glycated Haemoglobin (HbA1c) in the Diagnosis of Diabetes Mellitus 6-7.
- Ahmed MH, Byrne CD. (2009)** Current treatment of nonalcoholic fatty liver disease. Diabetes Obes Metab 11, 188–195.
- Akalin S, Berntorp K, Ceriello A. (2009)** Intensive glucose therapy and clinical implications of recent data: a consensus statement from the Global Task Force on Glycaemic Control. Int J Clin Pract 63, 1421–1425.
- Akashapati Gairola, Arthasastra of Kautilya (1970)** 14, 177-190.
- Ambady R, Chamukuttan S, Shetty AS, Nanditha A. (2012)** Trends in prevalence of diabetes in Asian countries. World J Diabetes 15, 3(6), 110-117.
- American Diabetes Association (1998).** Screening for diabetes. Diabetes Care 21, (suppl 1):s20-s22.
- American Diabetes Association (2012)** Diabetes Care 35, s64-s71.
- American Diabetes Association Expert Committee (1997)** Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 20, 1183-97.
- American Diabetes Association.** All about Diabetes. <http://www.diabetes.org/about-diabetes.jsp> (accessed 10 Feb 2009).
- American Diabetic Association (2011)** Standards of medical care in diabetes Diabetes Care 34, (Suppl 1), s11–s61.
- Amori RE, Lau J, Pittas AG. (2007)** Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis, JAMA 298, 194–206.
- Anderson JW, Kendall CW, Jenkins DJ (2003)** Importance of weight management in type 2 diabetes: review with metaanalysis of clinical studies. J Am Coll Nutr 22, 331–339.
- Andrew JK, Clifford JB. (2005)** Oral Antidiabetic Agents Current Role in Type 2 Diabetes Mellitus Drugs 65(3), 385-411.

- Anjana RM**, Pradeepa R, Deepa M. (2011) *Diabetologia* 54(12), 3022-3027, DOI: 10.1007/s00125-011-2291-5.
- Anjana RM**, Pradeepa R, Deepa M, Datta M, Sudha V, Unnikrishnan R, Bhansali A, Joshi SR, Joshi PP and Yajnik CS. (2011) Prevalence of Diabetes and Pre-Diabetes and Associated Risk Factors among Tuberculosis Patients in India; *Diabetologia* 54, 3022-3027.
- Armstrong DG**, Lavery LA, Veal SA. (1998). Choosing a practical screening instrument to identify patients at risk for diabetic foot ulceration. *Arch Intern Med* 158, 289-292.
- Armstrong DG**. (2000) The 10-g monofilament: the diagnostic divining rod for the diabetic foot? *Diabetes Care* 23, 887.
- Aryangat AV**, Gerich JE. (2010) Type 2 diabetes: postprandial hyperglycemia and increased cardiovascular risk, *Vasc Health Risk Manag.* 6, 145–155.
- Asano N**. (2003) Glycosidase inhibitors: update and perspectives on practical use. *Glycobiology*, 13(10), 93-104.
- Aschner P**, Katzeff HL, Guo H. (2010) Efficacy and safety of monotherapy of sitagliptin compared with metformin in patients with type 2 diabetes. *Diabetes Obes Metab* 12, 252–261.
- Ashcroft FM**, Gribble FM. (1999) ATP-sensitive K⁺ channels and insulin secretion: their role in health and disease. *Diabetologia* 42, 903-919.
- Atal CK**, Sharma ML, Kaul A, Khajuria A. (1986). Immunomodulating agents of plant origin. I: Preliminary screening. *J Ethnopharmacol* 18, 133-141.
- Ayalasomayajula SP**, Dole K, He YL. (2007). Evaluation of the potential for steady-state pharmacokinetic interaction between vildagliptin and simvastatin in healthy subjects. *Curr Med Res Opin* 23, 2913–2920.
- Bailey CJ**, Day C, Krentz AJ. (2003) (A) Nice timing for glitazones. *Br J Diabetes Vasc Dis* 3, 366-367.
- Bailey CJ**, Day C. (2003) (B) Antidiabetic drugs. *Br J Cardiol* 10, 128-136.
- Bailey CJ**, Turner RC. (1996) Metformin. *N Engl J Med* 334, 574-579.

- Baldwin SJ**, Clarke SE, Chenery RJ. (1999) Characterisation of the cytochrome P450 enzymes involved in the in vitro metabolism of rosiglitazone. *Br J Clin Pharmacol* 48, 424-432.
- Bantle JP**, Wylie-Rosett J, Albright AL. (2008) Nutrition recommendations and interventions for diabetes: a position statement of the American Diabetes Association. *Diabetes Care* 31, (Suppl 1), s61-s78.
- Bayer HealthCare AG**: Glucobay product website. [<http://www.glucobay.com>] accessed February 2006.
- Bearse MA Jr**, Han T, Schneck ME. (2004) Local multifocal oscillatory potential abnormalities in diabetes and early diabetic retinopathy. *Invest ophthalmol Vis Sci* 45, 3259-3265.
- Bell DSH**. (2003) B-cell rejuvenation with thiazolidinediones. *Am J Med* 115(8A), 20s-23s.
- Bergman AJ**, Cote J, Maes A. (2009) Effect of sitagliptin on the pharmacokinetics of simvastatin. *J Clin Pharmacol* 49, 483-488.
- Bergman AJ**, Stevens C, Zhou Y. (2006) Pharmacokinetic and pharmacodynamic properties of multiple oral doses of sitagliptin, a dipeptidylpeptidase-IV inhibitor: a double-blind, randomized, placebo-controlled study in healthy male volunteers. *Clin Ther* 28, 55-72.
- Bergstrom RW**, Newell-Morris LL, Leonetti DL, Shuman WP, Wahl PW, Fujimoto WY. (1990) Association of elevated fasting C-peptide level and increased intra-abdominal fat distribution with development of NIDDM in Japanese-American men. *Diabetes* 39(1), 104-111.
- Berson SA**, Yalow RS. (1963) Antigens in Insulin Determinants of Specificity of Porcine Insulin in Man. *Science* 139, 844-845.
- Bingley PJ**, Bonifacio E, Williams AJ, Genovese S, Bottazzo GF, Gale EA. (1997) Prediction of IDDM in the general population: strategies based on combinations of autoantibody markers. *Diabetes* 46, 1701-10.
- Blech S**, Ludwig-Schwellinger E, Graefe-Mody EU, Withopf B, Wagner K. (2010) The metabolism and disposition of the oral dipeptidyl peptidase-4 inhibitor, linagliptin, in humans. *Drug Metab Dispos* 38, 667-678.

- Blonde L. (2010)** Current antihyperglycemic treatment guidelines and algorithms for patients with type 2 diabetes mellitus. *Am J Med* 123 (Suppl 3), s12–s18.
- Bloomgarden ZT, Inzucchi SE. (2007)** New treatments for diabetes. *N Engl J Med* 356, 2219–2220.
- Bodmer M, Meier C, Kraenzlin ME, Meier CR. (2009)** Risk of fractures with Glitazones: a critical review of the evidence to date. *Drug Saf* 32, 539–547.
- Bolli G, Dotta F, Rochotte E, Cohen SE. (2008)** Efficacy and tolerability of vildagliptin vs. pioglitazone when added to Metformin: a 24-week, randomized, double-blind study. *Diabetes Obes Metab* 10, 82–90.
- Bonifacio E, Bingley PJ. (1997)** Islet autoantibodies and their use in predicting insulin-dependent diabetes. *Acta Diabetol* 34, 185-193.
- Bonora E, Muggeo M. (2001)** Postprandial blood glucose as a risk factor for cardiovascular disease in Type II diabetes: the epidemiological evidence, *Diabetologia* 44, 2107-2114.
- Bornstein J, Lawrence RD. (1951)** Plasma Insulin in Human Diabetes Mellitus. *BMJ* 2, 1541.
- Boule NG, Haddad E, Kenny GP, Wells GA, Sigal RJ. (2001)** Effects of exercise on glycemic control and body mass in type 2 diabetes mellitus: a meta-analysis of controlled clinical trials. *JAMA* 86, 1218–1227.
- Boulton DW, Gerald M. (2007)** Safety, tolerability, pharmacokinetics and pharmacodynamics of once daily oral doses of saxagliptin for 2 weeks in type 2 diabetic and healthy subjects (Poster 0606-P). *Diabetes* 56, (Suppl. 1) A161.
- Braun D, Schonherr U, Mitzkat HJ. (1996)** Efficacy of acarbose monotherapy in patients with type 2 diabetes: A double-blind study conducted in general practice. *Endocrinology and Metabolism*, 3, 275-280.
- Buch HN, Baskar V, Barton DM. (2002)** Combination of insulin and thiazolidinedione therapy in massively obese patients with type 2 diabetes. *Diabetic Med* 19, 572-574.
- Buchanan TA, Xiang AH, Peters RK. (2002)** Preservation of pancreatic beta-cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high-risk hispanic women. *Diabetes* 51, 2796-803.

- Butler PC**, Matveyenko AV, Dry S, Bhushan A, Elashoff R. (2010) Glucagon-like peptide-1 therapy and the exocrine pancreas: innocent bystander or friendly fire? *Diabetologia* 53, 1–6.
- Byron JH.** (2005) Review complications of diabetes mellitus, *int. J. Diab. Dev. Countries* 25, 63-69.
- Campbell IW.** (2000) Antidiabetic drugs past and future: will improving insulin resistance benefit cardiovascular risk in type 2 diabetes mellitus? *Drugs* 60(5), 1017-1028.
- Ceriello A.** (2005) Postprandial hyperglycemia and diabetes complications: is it time to treat? *Diabetes.* 54(1), 1-7.
- Chakraborty R**, Rajagopalan R. (2002) Diabetes and insulin resistance associated disorders: disease and the therapy. *Current Science* 83, 1533-1538.
- Chan JC**, Chan KW, Ho LL. (1998) An Asian multicenter clinical trial to assess the efficacy and tolerability of acarbose compared with placebo in type 2 diabetic patients previously treated with diet. Asian Acarbose Study Group. *Diabetes Care* 21(7), 1058-1061.
- Chan JC.** (2009) Diabetes in Asia: epidemiology, risk factors, and pathophysiology. *JAMA* 301, 2129–2140.
- Chiarson JC**, Josse RG, Hunt JA. (1994) The efficacy of acarbose in the treatment of patients with insulin dependant diabetes mellitus a multicentric controlled clinical trial. *Ann Intern Med* 121, 928-935.
- Chiasson JL**, Josse RG, and Gomis R. (2002) Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial. *Lancet* 359, 2072.
- Chiasson JL**, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M. (2004) STOPNIDDM Trial Research Group 2003 Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial. *JAMA* 290, 486–494.
- Chiasson JL**, Josse RG, Gomis R. (2003) Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial. The STOP-NIDDM trial Research Group. *JAMA* 290, 486-494.

- Chiasson JL**, Naditch L. (2001) The Synergistic Effect of Miglitol Plus Metformin Combination Therapy in the Treatment of Type 2 Diabetes Diabetes Care 24,989–994.
- Christopher R**, Covington P, Davenport M. (2008) Pharmacokinetics, pharmacodynamics, and tolerability of single increasing doses of the dipeptidyl peptidase-4 inhibitor alogliptin in healthy male subjects. Clin Ther 30, 513–527.
- Chu XY**, Bleasby K, Yabut J (2007) Transport of the dipeptidyl peptidase-4 inhibitor sitagliptin by human organic anion transporter 3, organic anion transporting polypeptide 4C1, and multidrug resistance P-glycoprotein. J Pharmacol Exp Ther 321, 673–683.
- Collene AL**, Hertzler SR, Williams JA, Wolf BW. (2005) Nutrition. Effects of a nutritional supplement containing *Salacia oblonga* extract and insulinogenic amino acids on postprandial glycemia, insulinemia, and breath hydrogen responses in healthy adults. Nutrition 21(7-8), 848-854.
- Concannon P**, Gogolin-Ewens KJ, Hinds DA. (1998) A second-generation screen of the human genome for susceptibility to insulin-dependent diabetes mellitus. Nat Genet 19, 292-296.
- Coniff RF**, Shapiro JA, Robbins D. (1995) Reduction of glycosylated haemoglobin and postprandial hyperglycemia by acarbose in patients with NIDDM. A placebo-controlled dose-comparison study. Diabetes Care 18, (6), 817-824.(A)
- Coniff RF**, Shapiro JA, Seaton TB. (1994) Long-term efficacy and safety of acarbose in the treatment of obese subjects with non-insulindependent diabetes mellitus. Arch Intern Med 154 (21), 2442-2448.
- Coniff RF**, Shapiro JA, Seaton TB. (1995) Multicenter, placebocontrolled trial comparing acarbose (BAY g 5421) with placebo, tolbutamide, and tolbutamide-plus-acarbose in non-insulindependent diabetes mellitus. Am J Med 98(5), 443-451.(B)
- Covington P**, Christopher R, Davenport M. (2008) Pharmacokinetic, pharmacodynamic, and tolerability profiles of the dipeptidyl peptidase-4 inhibitor alogliptin: a randomized, double-blind, placebocontrolled, multiple-dose study in adult patients with type 2 diabetes. Clin Ther 30, 499–512.

- Cox NJ**, Frigge M, Nicolae DL. (1999) Loci on chromosomes 2 (NIDDM1) and 15 interact to increase susceptibility to diabetes in Mexican Americans. *Nat Genet* 21, 213-215.
- Cusi K**, DeFronzo RA. (1998) Metformin: a review of its metabolic effects. *Diabetes Rev* 6, 89-131.
- Das AK**, Shah S. (2011) History of Diabetes: From Ants to Analogs *JAPI* 59, 6-7.
- Davies M.** (2002) Nateglinide: better post-prandial glucose control. *Prescriber* 13, 17-27.
- Davis SN**, Johns D, Maggs D, Xu H, Northrup JH, and Brodows RG. (2007) Exploring the Substitution of Exenatide for Insulin in Patients With Type 2 Diabetes Treated With Insulin in Combination With Oral Antidiabetes Agents *Diabetes Care* 30(11), 2767-2772.
- Day C.** (1999) Thiazolidinediones: a new class of antidiabetic drugs. *Diabetic Med* 16, 1-14.
- DECODE Study Group** (2001) Glucose tolerance and cardiovascular mortality. Comparison of fasting and 2-hour diagnostic criteria. *Arch Intern Med* 161, 397-405.
- DeFronzo RA.** (1999) Pharmacologic therapy for type 2 diabetes mellitus. *Ann Intern Med* 131, 281-303.
- Derek LeRoith**, Simeon I, Taylor M.D, Jerrold MO. (2004) *Diabetes Mellitus: A Fundamental and Clinical Text*, 460.
- Derek LeRoith**, Simeon I. Taylor, M.D., Jerrold MO. (2004) *Diabetes Mellitus: A Fundamental and Clinical Text 3rd Edition*, Lippincott Williams & Wilkins 1304.
- Derosa G**, Maffioli P. (2012) α -Glucosidase inhibitors and their use in clinical practice. *Arch Med Sci* 5, 889-906.
- Derosa G**, Salvadeo SA, D'Angelo A. (2009) Metabolic effect of repaglinide or acarbose when added to a double oral antidiabetic treatment with sulphonylureas and metformin: a double-blind, cross-over, clinical trial. *Curr Med Res Opin* 25, 607-615.

- Desbuquois B, Postel MC, Vinay. (1980)** Receptor-mediated internalisation of insulin, glucagon and growth hormone in intact rat liver - a biochemical study, in *Insulin: Chemistry, Structure and Function of Insulin and Related Hormones: Proceedings 2nd Int. Insulin Symposium, Aachen, 4-7 Sep 1979*, eds. D. Brandenburg and A. Wollmer, de Gruyter, Berlin, New York 285-292.
- Diabetes Control and Complications Trial Research Group (1995)** The relationship of glycemic exposure (HbA_{1c}) to the risk of development and progression of retinopathy in the Diabetes Control and Complications Trial. *Diabetes* 44(968), 1160.
- Diabetes Prevention Program Research Group (2002)** Reduction of the incidence of type 2 diabetes with lifestyle intervention or metformin. *N Engl J Med* 346, 393-403.
- Dittberner S, Duval V, Staab A, Troconiz I, Graefe-Mody U, Jaehde U. (2007)** Determination of the absolute bioavailability of BI 1356, a substance with nonlinear pharmacokinetics, using a population pharmacokinetic modelling approach (abstract 1110). Poster presented at 16th Annual Meeting of the Population Approach Group in Europe, København, Denmark; Available from URL: <http://www.page-meeting.org/?abstract=1110>. Accessed 5 July 2010.
- Dore DD, Seeger JD, Arnold Chan K. (2009)** Use of a claims-based active drug safety surveillance system to assess the risk of acute pancreatitis with exenatide or sitagliptin compared to metformin or glyburide. *Curr Med Res Opin* 25, 1019–1027.
- Dornhorst A. (2001)** Insulotropic meglitinide analogues. *Lancet* 358, 1709-1715.
- Drent ML, Tollefsen AT, Heusden FH. (2002)** Dose-dependent efficacy of miglitol, a α -glucosidase inhibitor, in type 2 diabetic patients on diet alone: Results of a 24-week double-blind placebocontrolled study. *Diabetes Nutr Metab* 15, 152-159.
- Duc Son LN, Kusama K, Hung NT, Loan TT, Chuyen NV, Kunii D, Sakai T, Yamamoto S. (2004)** Prevalence and risk factors for diabetes in Ho Chi Minh City, Vietnam. *Diabet Med* 21, 371-376
- Elliott P. Joslin. (1922)** "Today's Problems in Light of Nine Hundred and Thirty Fatal Cases," *JAMA* 78(20), 1506-1510.

- Elmer PJ**, Obarzanek E, Vollmer WM. (2006) Effects of comprehensive lifestyle modification on diet, weight, physical fitness, and blood pressure control: 18-month results of a randomized trial. *Ann Intern Med* 144, 485–495.
- Engel SS**, Williams-Herman DE, Golm GT. (2010) Sitagliptin: Review of preclinical and clinical data regarding incidence of pancreatitis. *Int J Clin Pract* 64, 984–990.
- Engelgau MM**, Thompson TJ, Herman WH. (1997) Comparison of fasting and 2 hr glucose and HbA1C level for diagnosing diabetes. Diagnosis criteria and performance revisited. *Diabetes Care* 20, 785-791.
- Espinal J.** (1989) *Understanding Insulin Action: Principles and molecular mechanisms*, Ellis Horwood, Chichester 13-16.
- European Diabetes Policy Group.** (1999) A desktop guide to type 2 diabetes mellitus. *Diabetic Med* 16, 716-730.
- European Medicines Agency (EMA)(A).** Galvus (vildagliptin)—European public assessment report (EPAR)—scientific discussion. Available from URL: <http://www.emea.europa.eu/humandocs/PDFs/EPAR/galvus/H-771-en6.pdf>. Accessed 5 July 2010.
- European Medicines Agency (EMA)(B).** Onglyza (saxagliptin)—European public assessment report (EPAR)—CHMP Assessment Report. Available from URL: <http://www.emea.europa.eu/humandocs/PDFs/EPAR/onglyza/H-1039-en6.pdf>. Accessed 5 July 2010.
- Evans AJ**, Krentz AJ. (1999) Glimperide: a new sulphonylurea. *Prescriber* 10, 51-58.
- Expert Committee on the Diagnosis and Classification of Diabetes Mellitus (2009)** Diagnosis and Classification of Diabetes Mellitus. *Diabetes Care* 32 (suppl 1) s62-s67.
- Fasshauer M**, Paschke R. (2003) Regulation of adipocytokines and insulin resistance. *Diabetologia* 46, 1594-1603.
- Ferrannini E**, Fonseca V, Zinman B. (2009). Fifty-two-week efficacy and safety of vildagliptin vs. glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin monotherapy. *Diabetes Obes Metab* 11, 157–166.

- Fischer S**, Hanefeld M, Spengler M, Boehme K, Temelkova-Kurktschiev T. (1998) European study on dose-response relationship of acarbose as a first-line drug in non-insulin-dependent diabetes mellitus: efficacy and safety of low and high doses. *Acta Diabetol* 35, 34–40.
- Flammang AM**, Erexson GL, Mecchi Ms, Murli H. (2006) Genotoxicity testing *Salacia oblonga* Extract. *Food Chem. Toxicol* 44 (11), 1868-1874.
- Flammang AM**. (2007) Toxicological and cytogenetic assessment of *Salacia oblonga* extract in rat subchronic study. *Food Chem. Toxicol* 45, 1954 – 1962.
- Frantz S**, Calvillo L, Tillmanns J, Elbing I, Dienesch C, Bischoff H, Ertl G and Bauersachs J. (2005) Repetitive postprandial hyperglycemia increases cardiac ischemia/reperfusion injury: prevention by the alphagucosidase inhibitor acarbose, *FASEB J.* 19, 591-593.
- Fuchs H**, Tillement JP, Urien S, Greischel A, Roth W. (2009) Concentrationdependent plasma protein binding of the novel dipeptidyl peptidase 4 inhibitor BI 1356 due to saturable binding to its target in plasma of mice, rats and humans. *J Pharm Pharmacol* 61, 55–62.
- Fura A**, Khanna A, Vyas V. (2009) Pharmacokinetics of the dipeptidyl peptidase 4 inhibitor saxagliptin in rats, dogs, and monkeys and clinical projections. *Drug Metab Dispos* 37, 1164–1171.
- Gallagher EJ**, Bloomgarden ZT, Le Roith D. (2009) Review of hemoglobin A1c in the management of diabetes. *Journal of Diabetes* 1, 09-17.
- Gandhi GY**, Murad MH, Fujiyoshi A. (2008) Patientimportant outcomes in registered diabetes trials. *JAMA* 299, 2543–2549.
- Ganie MA**, Kotwal S. (2012) Recent Advances in Management of Diabetes Mellitus;*JIMSA* 25(3), 171-175.
- Gerstein HC**, Miller ME, Byington RP. (2008) Effects of intensive glucose lowering in type 2 diabetes. *N Engl J Med* 358, 2545–2559.
- Ginsberg HN**. (2000) Insulin resistance and cardiovascular disease. *J. Clin Invest*; 106, 453-458.

- Glasgow RE**, Peeples M, Skovlund SE. (2008) Where is the patient in diabetes performance measures? The case for including patient-centered and self-management measures. *Diabetes Care* 31, 1046–1050.
- Gordon NF**, Salmon RD, Franklin BA. (2004) Effectiveness of therapeutic lifestyle changes in patients with hypertension, hyperlipidemia, and/or hyperglycemia. *Am J Cardiol* 94, 1558–1561.
- Gosh MJ**. (2005) Trial of low glyceemic diet and acarbose therapy for control of postprandial hyperglycemia in type 2 diabetes mellitus: preliminary report. *Int. J. Diab. Dev. Countries* 25, 80-84.
- Graefe-Mody EU**, Padula S, Ring A, Withopf B, Dugi KA. (2009) Evaluation of the potential for steady-state pharmacokinetic and pharmacodynamic interactions between the DPP-4 inhibitor linagliptin and metformin in healthy subjects. *Curr Med Res Opin* 25, 1963–1972.
- Graefe-Mody U**, Huettner S, Staehle H, Ring A, Dugi KA. (2010) Effect of linagliptin (BI 1356) on the steady-state pharmacokinetics of simvastatin. *Int J Clin Pharmacol Ther* 48, 367–374.
- Graydon SM**, Edmond AR, Jerry R, David CW, Lau JF, Yale JM, Jean LC, Remi RL, Pierre M, Daniel T, Thomas Wolever, RG, Josse DE. (2000) Effect of acarbose on insulin sensitivity in elderly patients with diabetes, *diabetes care* 23, 1162–1167.
- Gribble FM**, Reimann F. (2002) Pharmacological modulation of KATP channels. *Biochem Soc Trans* 30, 333-339.
- Groop LC**. (1992) Sulfonylureas in NIDDM. *Diabetes Care* 15, 1737-1754.
- Haffner SM**. (1998) Epidemiology of type 2 diabetes: risk factors. *Diabetes Care* 21(Suppl 3), c3-c6.
- Hanefeld M**, Cagatay M, Petrowitsch T, Neuser D, Petzinna D, Rupp M. (2004) (A) Acarbose reduces the risk for myocardial infarction in type 2 diabetic patients: meta-analyses of seven long-term studies. *European Heart Journal* 25 (10-16), 163.
- Hanefeld M**, Chiasson JL, Koehler C, Henkel E, Schaper F, Temelkova-Kurktschiev T. (2004)(B) Acarbose slows progression of intima-media thickness of the

- carotid arteries in subjects with impaired glucose tolerance. *Stroke* 35, 1073-1078.
- Hanefeld M**, Fischer S, Schulze J. (1991) Therapeutic potentials of acarbose as first-line drug in NIDDM insufficiently treated with diet alone. *Diabetes Care* 14(8), 732-737.
- Hanson RL**, Ehm MG, Pettitt DJ. (1998). An autosomal genomic scan for loci linked to type II diabetes mellitus and body-mass index in Pima Indians. *Am J Hum Genet* 63, 1130-1138.
- Harris MI**, Cowie CC, Reiber G. (1995) eds. *Diabetes in America*, 2nd ed. Washington, DC: U.S. Government Printing Office. 15-36.
- Harris MI**, Robbins DC. (1994) Prevalence of adult-onset IDDM in the U.S. population. *Diabetes Care* 17, 1337.
- Hasche H**, Mertes G, Bruns C, Englert R, Genthner P, Heim D, Heyen P, Mahla G, Schmidt C, Schulze-Schleppinghof B, Steger-Johannsen G. (1999) Effects of acarbose treatment in type 2 diabetic patients under dietary training: a multicentre, double-blind, placebo-controlled, 2-year study. *Diabetes Nutr Metab* 12, 277-285.
- He H**, Tran P, Yin H. (2009) Absorption, metabolism, and excretion of [¹⁴C]vildagliptin, a novel dipeptidyl peptidase 4 inhibitor, in humans. *Drug Metab Dispos* 37, 536-544.
- He YL**, Sabo R, Picard F. (2009) Study of the pharmacokinetic interaction of vildagliptin and metformin in patients with type 2 diabetes. *Curr Med Res Opin* 25, 1265-1272.
- He YL**, Sadler BM, Sabo R. (2007). The absolute oral bioavailability and population-based pharmacokinetic modelling of a novel dipeptidylpeptidase-IV inhibitor, vildagliptin, in healthy volunteers. *Clin. Pharmacokinet* 46, 787-802.
- Heacock PM**, Hertzler SR, Williams JA, Wolf BW. (2005) Effects of a medical food containing an herbal alpha-glucosidase inhibitor on postprandial glycemia and insulinemia in healthy adults *J Am Diet Assoc.* 105 (1), 65-71.
- Heise T**, Graefe-Mody EU, Hu" tner S, Ring A. (2009) Trommeshausen D, Dugi KA. Pharmacokinetics, pharmacodynamics and tolerability of multiple oral doses of

linagliptin, a dipeptidyl peptidase-4 inhibitor in male type 2 diabetes patients. *Diabetes Obes Metab* 11, 786–794.

Herman GA, Bergman A, Yi B, Kipnes M. (2006) Tolerability and pharmacokinetics of metformin and the dipeptidyl peptidase-4 inhibitor sitagliptin when co-administered in patients with type 2 diabetes. *Curr Med Res Opin* 22, 1939–1947.

Herman GA, Stein PP, Thornberry NA, Wagner JA. (2007) Dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes: focus on sitagliptin. *Clin Pharmacol Ther* 81, 761–767.

Herman GA, Stevens C, Van Dyck K. (2005). Pharmacokinetics and pharmacodynamics of sitagliptin, an inhibitor of dipeptidyl peptidase IV, in healthy subjects: results from two randomized, double-blind, placebo-controlled studies with single oral doses. *Clin Pharmacol Ther* 78, 675–688.

Hermann LS, Lindberg G, Lindblad U. (2002). Efficacy, effectiveness and safety of sulphonylurea-metformin combination therapy in patients with type 2 diabetes. *Diabetes Obes Metab* 4, 296-304.

Herrera V, Aubert R, Tully L. Pancreatitis in patients treated with exenatide or sitagliptin. 69th Scientific Sessions of the American Diabetes Association, 2009; Late-breaking abstract no. 10-LB. Available from URL: http://professional.diabetes.org/Abstracts_Display.aspx?TYP=1&CID=74851. Accessed 5 July 2009.

Himsworth HP. (1936) Diabetes Mellitus: Its Differentiation Into Insulin-Sensitive and Insulin-Insensitive Types. *Lancet* 1, 117.

Hoffmann J, Spengler M. (1994) The Essen Study Efficacy of 24 Week Monotherapy With Acarbose, Glibenclamide, or Placebo in NIDDM Patients. *Diabetes Care* 17, 561-565.

Hotta N, Kakuta H, Sano T, Matsumae H, Yamada H, Kitazawa S, Sakamoto N. (1993) Long-term effect of acarbose on glycaemic control in non-insulin-dependent diabetes mellitus: a placebo-controlled double-blind study. *Diabet Med* 10(2), 134-138.

- Hove MN, Kristensen JK, Lauritzen T, Bek T. (2004)** The prevalence of retinopathy in an unselected population of type 2 diabetes patients from Aarhus county, Denmark. *Acta Ophthalmol Scand* 82, 443-448.
- Howlett HCS, Bailey CJ. (2000)** A risk-benefit assessment of metformin in type 2 diabetes mellitus. In: Krentz AJ, editor. *Drug treatment of type 2 diabetes*. Auckland: Adis Books 61-76.
- Huang C, Kim Y, Caramori ML. (2002)** Cellular basis of diabetic nephropathy: II. The transforming growth factor - beta system and diabetic nephropathy lesions in type 1 diabetes. *Diabetes* 51, 577 -581.
- ICMR Guidelines for Management of Type 2 Diabetes- 2005.**
- IDF Diabetes Atlas, 2009.** 4th edition. International Diabetes Federation.
- Im R, Mano H, Nakatani S, Shimizu J and Wada M. (2008)** Aqueous extract of *Kothala himbatu* (*Salacia reticulata*) stems promotes oxygen consumption and suppresses body fat accumulation in mice. *Journal of Health Science* 54(6), 645-653.
- International Committee Report** on the role of the A1C assay in the diagnosis of diabetes (2009) *Diabetes Care* 32, 1327-1334.
- International Diabetes Federation. (2009)** *Diabetes Atlas*. 4th edn. Brussels: International Diabetes Federation.
- International Diabetes Federation. Global burden (2011)** *IDF Diabetes Atlas*. 5th edition.
- International Diabetes Federation, Update 2012.** *IDF Diabetes Atlas*..
- Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M, Peters AL, Tsapas A, Wender A, Matthews DR. (2012)** Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD), *Diabetologia*, DOI 10.1007/s00125-012-2534-2540.
- Is diabetes troubling you? (2005)** Take *Salacia oblonga*. *Jim*, 12 -28.

- Ismail-Beigi F**, Moghissi E, Tiktin M, Hirsch IB, Inzucchi SE, Genuth S. (2011) Individualizing glycemic targets in type 2 diabetes mellitus: implications of recent clinical trials. *Ann Intern Med* 154, 554–559.
- Jack DeRuiter**. (2003) Overview of antidiabetic agent; *Endocrine Pharmacotherapy Module*, Spring 04.
- Janus ED**, Watt NM, Lam KS, Cockram CS, Siu ST, Liu LJ, Lam TH. (2000) The prevalence of diabetes, association with cardiovascular risk factors and implications of diagnostic criteria (ADA 1997 and WHO 1998) in a 1996 community-based population study in Hong Kong Chinese. Hong Kong Cardiovascular Risk Factor Steering Committee. *American Diabetes Association. Diabet Med* 17, 741-745.
- Johnson JA**, Majumdar SR, Simpson SH. (2002) Decreased mortality associated with sulfonylurea monotherapy in type 2 diabetes. *Diabetes Care* 25, 2244-2248.
- Johnston PS**, Feig PU, Coniff RF, Krol A, Kelley DE, Mooradian AD. (1998) Chronic treatment of African-American type 2 diabetic patients with alpha-glucosidase inhibition. *Diabetes Care* 21(3), 416-422 (A).
- Johnston PS**, Lebovitz HE, Coniff RF, Simonson DC, Raskin P, Munera CL. (1998) Advantages of alpha-glucosidase inhibition as monotherapy in elderly type 2 diabetic patients. *J Clin Endocrinol Metab* 83(5), 1515-22(B).
- Jones KL**. (1998) Non-insulin dependent diabetes in children and adolescents: the therapeutic challenge. *Clin Pediatr (Phila)* 37, 103-110.
- Joshi SR**, Parikh RM, Das AK. (2007) Insulin History, Biochemistry, Physiology and Pharmacology; *JAPI* 55, 19-26.
- Josse RG**, Chiasson JL, Ryan EA, Lau DC, Ross SA, Yale JF, Leiter LA, Maheux P, Tessier D, Wolever TM, Gerstein H, Rodger NW, Dornan JM, Murphy LJ, Rabasa-Lhoret R, Meneilly GS. (2003) Acarbose in the treatment of elderly patients with type 2 diabetes. *Diabetes Res Clin Pract* 59, 37–42.
- Kajimoto O**, Kawamuri S, Shimoda H, Kawahara Y, Hirata H and Takahashi T. (2000) Effects of diet containing *Salacia reticulata* on mild type 2 diabetes in humans - A placebo controlled cross over trial. *Journal Japanese Society of Nutrition and Food Science* 53, 199–205.

- Kameswara Rao B**, Renuka Sudarshan P, Rajasekhar MD, Nagaraju N, Appa Rao Ch. (2003) Hypoglycemic activity of Terminalia pallida fruit in alloxan induced diabetic rats. *J Ethnopharmacology* 85, 169-172.
- Kaprio J**, Tuomilehto J, Koskenvuo M. (1992). Concordance for type I (insulin-dependent) and type 2 (non-insulin-dependent) diabetes mellitus in a population-based cohort of twins in Finland. *Diabetologia* 35, 1060-1067.
- Karen SL**, Lam SC, Tlu MW, Tsang TR, Sidney IP, Tam CF. (1998) Acarbose in NIDDM Patients With Poor Control on Conventional Oral Agents A 24-week placebo-controlled study, *Diabetes Care* 21, 1154-1158.
- Karim A**, Bridson WE, Fleck P. (2007) Disposition of the dipeptidyl peptidase-4 inhibitor [14C]alogliptin benzoate ([14C]SYR-322) after oral administration to healthy male subjects (Abstract). AAPS Annual Meeting and Exposition, 9–15.
- Karim A**, Covington P, Christopher R. (2010) Pharmacokinetics of alogliptin when administered with food, metformin, or cimetidine: a two-phase, crossover study in healthy subjects. *Int J Clin Pharmacol Ther* 48, 46–58.
- Karim A**, Laurent A, Munsaka M, Wann E, Fleck P, Mekki Q. (2009) Coadministration of pioglitazone or glyburide and alogliptin: pharmacokinetic drug interaction assessment in healthy participants. *J Clin Pharmacol* 49, 1210–1219.
- Karvonen M**, Tuomilehto J, Libman I, LaPorte R. (1993) For the World Health Organization DIAMOND Project Group A review of the recent epidemiological data on the worldwide incidence of type 1 (insulin-dependent) diabetes mellitus. *Diabetologia* 36, 883-892.
- King H**, Aubert RA, Herman WH. (1998) Global burden of diabetes, 1995-2025. *Diabetes Care* 21, 1414-1431.
- Kirpichnikov D**, McFarlane SI, Sowers JR. (2002) Metformin: an update. *Ann Intern Med* 137, 25-33.
- Klein S**, Sheard NF, Pi-Sunyer X. (2004) Weight management through lifestyle modification for the prevention and management of type 2 diabetes: rationale and strategies: a statement of the American Diabetes Association, the North

- American Association for the Study of Obesity, and the American Society for Clinical Nutrition. *Diabetes Care* 27, 2067–2073
- Knip M. (1997)** Disease-associated autoimmunity and prevention of insulin-dependent diabetes mellitus. *Ann Med* 29, 447-451.
- Kolb H, Dannehl K, Gruneklee D. (1988)** Prospective analysis of islet cell antibodies in children with type 1 (insulin-dependent) diabetes. *Diabetologia* 31, 189-194.
- Koyasu M, Ishii H, Watarai M, Takemoto K, Inden Y, Takeshita K, Amano T, Yoshikawa D, Matsubara T. and Murohara T . (2010)** Impact of Acarbose on Carotid intima-media thickness in patients with newly diagnosed impaired glucose tolerance or mild type 2 diabetes mellitus: A one-year, prospective, randomized, open-label, parallel-group study in Japanese adults with established coronary artery disease, *Clin. Ther.* 32, 1610-1617.
- Krentz AJ, Bailey CJ. (2005)** Oral antidiabetic agents: Current Role in Type 2 Diabetes Mellitus. *Drugs*, 65(3), 385-411.
- Krentz AJ, Bailey CJ, Melander A. (2000)** Thiazolidinediones for type 2 diabetes. *BMJ* 321, 252-253.
- Krentz AJ, Bailey CJ. (2001)** Type 2 diabetes in practice. London: Royal Society of Medicine Press.
- Krentz AJ, Ferner RE, Bailey CJ. (1994)** Comparative tolerability profiles of oral antidiabetic agents. *Drug Saf* 11, 223-241.
- Krentz AJ. (2003)** Sulfonylureas in the prevention of vascular complications: from UKPDS to the ADVANCE study. Proceedings of the VIIIth European symposium on metabolism. Amsterdam: Elsevier Science International Congress Series 1253, 261-277.
- Krentz AJ. (2002)** Insulin resistance. Oxford: Blackwell Science,
- Kumar PJ, Clark M. (2002)** Textbook of Clinical Medicine. Pub: Saunders (London) 1099-1121.
- Laakso M, Pyorala K. (1985)** Age at onset and type of diabetes. *Diabetes Care* 8, 114-117.
- Lalau JD, Race JM. (2000)** Metformin and lactic acidosis in diabetic humans. *Diabetes Obes Metab* 2, 131-137.

- Landgraf R. (2000)** Meglitinide analogues in the treatment of type 2 diabetes mellitus. *Drugs Aging* 17(5), 411-425.
- Lasker SP, McLachlan CS, Wang L, Ali SMK, Jelinek HF (2010)** Discovery, treatment and management of diabetes; *Journal of Diabetology*, 1(1), 1-8.
- Lebovitz HE. (1998)** Alpha-glucosidase inhibitors as agents in the treatment of diabetes. *Diabetes Rev* 6, 132–145.
- Lee SJ, Eng C. (2011)** Goals of glycemic control in frail older patients with diabetes. *JAMA* 305, 1350–1351.
- Lei Chen, Dianna J. Magliano and Paul Z. Zimmet (2012)** The worldwide epidemiology of type 2 diabetes mellitus—present and future perspectives; *Nat. Rev. Endocrinol*, 8, 228–236.
- Li Y, Huang TH and Yamahara J (2008)** Salacia root, a unique Ayurvedic medicine, meets mul-tiple targets in diabetes and obesity. *Life Sci.* 82, 1045–1049.
- Ligueros-Saylan M, Foley JE, Schweizer A, Couturier A, Kothny W. (2010)** An assessment of adverse effects of vildagliptin versus comparators on the liver, the pancreas, the immune system, the skin and in patients with impaired renal function from a large pooled database of Phase II and II clinical trials. *Diabetes Obes Metab* 12, 495–509.
- Lord JM, Flight IHK, Norman RJ. (2003)** Metformin in polycystic ovary syndrome 327, 951-955.
- Lu FH, Yang YC, Wu JS, Wu CH, Chang CJ. (1998)** A population-based study of the prevalence and associated factors of diabetes mellitus in southern Taiwan. *Diabet Med* 15, 564-572.
- MacCracken J, Hoel D. (1997)** From ants to analogues:Puzzles and promises in diabetes management. *Postgraduate Medicine* 4(101), 138-140.
- Marten FMAC, Visseren FLJ, Lemay J. (2002)** Metabolic and additional vascular effects of thiazolidinediones. *Drugs* 62(10) 1463-1480.
- Massi Benedetti M. (2006)** Changing targets in treatment of Type 2 diabetes. *Curr Med Res Opin.* 22 (Suppl 2) s5-s13.
- Matsuda H, Morikawa T and Yoshikawa M. (2007)** Antidiabetogenic constituents from several nat-ural medicines. *Pure Appl. Chem.* 74(7), 1301–1308.

- May C, Montori VM, Mair FS, (2009)** We need minimally disruptive medicine. *BMJ* 339, b2803.
- McCance DR, Hanson RL, Charles MA. (1994)** Comparison of tests for glycated haemoglobin and fasting and two hour plasma glucose concentration as giagnostic method for diabetes. *BMJ*, 308, 1323-1328.
- Meijer JW, Smit AJ, Sonderen EV. (2002)** Symptom scoring systems to diagnose distal polyneuropathy in diabetes: the Diabetic Neuropathy Symptom score. *Diabet Med* 19, 962-965.
- Melton LJ, Palumbo PJ, Chu-pin CA. (1983)** Incidence of diabetes mellitus by clinical type. *Diabetes Care* 6, 75-86.
- Mistry GC, Bergman AJ, Zheng W. (2008)** Sitagliptin, an dipeptidyl peptidase-4 inhibitor, does not alter the pharmacokinetics of the sulphonylurea, glyburide, in healthy subjects. *Br J Clin Pharmacol* 66, 36–42.
- Mitrakou A, Tauntas N, Raptis AE. (1998)** Long term effectiveness of a new alpha glucosidase inhibitor (Miglitol) in insulin treated type 2 diabetes mellitus. *Diabetic medicine*.15, 657-660.
- Miyazaki M, Kubo M, Kiyohara Y. (2004)** Comparision of diagnostic method for diabetses Millitus based in prevalence of rationopathy in Japenes population: The Hisayama Study. *Diabetlogia*, 47, 1411-1415.
- Mohan V, Sandeep S, Deepa R, Shah B, Varghese C. (2007)** Epidemiology of type 2 diabetes: Indian scenario; *Indian J Med Res* 125, 217-230.
- Moran A, Palmas W, Field L. (2004)** Cardiovascular autonomic neuropathy is associated with microalbuminuria in older patients with type 2 iabetes. *Diabetes care* 27, 972-977.
- Moses A. (2011)** SUPPLEMENT TO JAPI 59, 23-24.
- Nabarrö JDN, Spencer AG, Stowers JM. (1952)** Metabolic studies in severe diabetic ketosis. *Q J Med* 82, 225-248.
- Nadkarni AK. (1954)** *Indian Materia Medica*. Popular Prakashan press
- Nadkarni KM (1993)** *The Indian Materia Medica*. Popular prakashan Pvt. Ltd., Bombay 1, 1089.

- Nathan DM**, Turgeon H, Regan S. (2007) Relationship between glycated hemoglobin levels and mean glucose levels over time. *Diabetologia* 50, 2239-2244.
- National Diabetes Data Group (1979)**. Classification and diagnosis of diabetes mellitus and other categories of glucose intolerance. *Diabetes* 28,1039-1057.
- National Diabetes Fact Sheet (2011)** 1-12.
- National Institute of Diabetes and Digestive and Kidney Diseases NIH publication no. 13-5094 1996**.
- National Institutes of Health Publication No. 95-1468 (1995)**, "Diabetes In America," 2nd edition 283-291.
- Nauck MA**, Meininger G, Sheng D, Terranella L, Stein PP. (2007) Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double-blind, non-inferiority trial. *Diabetes Obes Metab* 9, 194–205.
- Nepom GT**, Kwok WW. (1998) Molecular basis for HLA-DQ associations with IDDM. *Diabetes* 47, 1177-1184.
- Nesto RW**, Bell D, Bonow RO. (2003) Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and the American Diabetes Association. *Circulation* 108, 2941-2948.
- Neufeld ND**, Raffel LJ, Landon C (1998) Early presentation of type 2 diabetes in Mexican-American youth. *Diabetes Care* 21, 80-86.
- Newsholme EA**, SJ Bevan GD Dimitriadis RP. (1992) Kelly, in *Insulin: Molecular Biology to Pathology*, eds. F. M. Ashcroft and S. J. H. Ashcroft, IRL Press, Oxford, 155.
- Nicole AS**, Lynne LL. (2008) THERAPY IN PRACTICE, *Pediatr Drugs* 10 (4), 209-215.
- Niskanen LK**, Tuomi T, Karjalainen J. (1995) GAD antibodies in NIDDM: ten-year follow-up from the diagnosis. *Diabetes Care* 18, 1557-1565.
- Onglyza prescribing information**. Available from URL: http://packageinserts.bms.com/pi/pi_onglyza.pdf. Accessed 5 July 2010.

- Ono K**, Limbu YR, Rai SK, Kurokawa M, Yanagida J, Rai G, Gurung N, Sharma M, Rai CK. (2007) The prevalence of type 2 diabetes mellitus and impaired fasting glucose in semi-urban population of Nepal. *Nepal Med Coll J* 9, 154-156.
- Pagano G**, Marena S, Corgiat-Mansin L, Cravero F, Gioada C, Bozza M, Rossi CM (1995) Comparison of miglitol and glibenclamide in diet-treated type 2 diabetic patients. *Diabete Metab* 21, 162-167.
- Pan C**, Yang W, Barona JP. (2008) Comparison of vildagliptin and acarbose monotherapy in patients with Type 2 diabetes: a 24-week, double-blind, randomized trial. *Diabet Med* 25, 435-441.
- Partanen J**, Niskanen L, Lehtinen J. (1995) Natural history of peripheral neuropathy in patients with noninsulindependent diabetes. *N Engl J Med* 333, 89-94.
- Parulkar AA**, Pendergrass ML, Granda-Ayala R. (2001) Nonhy poglycemic effects of thiazolidinediones. *Ann Intern Med* 134, 61-71.
- Pertseva NM**, Shpakov AO, Plenseva SA, Kuznetsova LA (2003) A novel view on the mechanism of action of insulin and other insulin superfamily peptides involvement of adenylyl cyclase signalling system, *Comp. Biochem. Phys. B.* 134(1), 11-36.
- Pickup JC**, Willium G. (2003) The history of diabetes mellitus. In *Textbook of diabetes*. 3rd edn. Blackwell Science Limited, Oxford, London.1, 50-55.
- Pocock SJ**, Smeeth L. (2009) Insulin glargine and malignancy: an unwarranted alarm. *Lancet* 374, 511-513.
- Press Release**, 4th February (2008) Galvus®, a new treatment for patients with type 2 diabetes, receives European approval for label update paving the way for EU launches. Available from URL: <http://www.medicalnewstoday.com/articles/95931.php>. Accessed 5 July 2010.
- Qiao Q**, Tuomilehto J, Borch-Johnsen K. (2002) Post-challenge hyperglycaemia is associated with premature death and macrovascular complications. *Diabetologia* 46 (Suppl. 1), m17-21.
- Radha R**. Amrithaveni M (2009) Role of medicinal plant *Salacia Reticulata* in the management of Type II Diabetic Subjects, *Anc Sci Life*, 29(1), 14-16.

- Rahbar S**, Blumenfeld O, Ranney HM. (1969) Studies of unusual hemoglobin in patients with diabetes mellitus. *Biochem Biophys Res Commun*, 36, 838-834.
- Ramachandran A**, Das AK, Joshi SR, Yajnik CS, Shah S, Prasannakumar KM. (2010) Current status of diabetes in India and need for novel therapeutic agent. *JAPI(s)* 58, 7-9.
- Ramachandran A**, Snehalatha C, Dharmaraj D, Viswanathan M. (1992) Prevalence of glucose intolerance in Asian Indians. Urban-rural difference and significance of upper body adiposity. *Diabetes Care* 15,1348-1355.
- Ramachandran A**, Wan Ma RC, Snehalatha C. (2010) Diabetes in Asia. *Lancet* 375, 408-418.
- Reaven GM**. (1988) Role of insulin resistance in human disease. *Diabetes* 37(1), 595-607.
- Rendell M**. (2004) The role of sulfonylureas in the management of type 2 diabetes. *Drugs* 64(12), 1339-1358.
- Report of Expert Committee on the Diagnosis and Classification of Diabetes Mellitus**. *Diabetes Care* (1997) (20), 1183-1197.
- Richter B**, Bandeira-Echtler E, Bergerhoff K, Lerch CL. (2008) Dipeptidyl peptidase-4 (DPP-4) inhibitors for type 2 diabetes mellitus. *Cochrane Database Syst Rev* CD006739.
- Roberts AW**, Thomas A, Rees A. (2003) Peroxisome proliferator activated receptor- γ agonists in atherosclerosis: current evidence and future directions. *Curr Opin Lipidol* 14, 567-573.
- Roberts WL**, De BK, Brown D. (2002) Effect of hemoglobin C and S traits on eight glycohemoglobin methods. *Clin Chem* 48, 383-385.
- Rorsman P**, Renstrom E. (2003) Insulin granule dynamics in pancreatic beta cells. *Diabetologica* 46,1029-1045.
- Rosen ED**, Spiegelman BM. (2001) PPAR- γ : a nuclear regulator of metabolism, differentiation, and cell growth. *J Biol Chem* 276(37), 731-734.
- Rosenbaum P**, Peres RB, Zanella MT, Ferreira SRG. (2002) Improved glycemic control by acarbose therapy in hypertensive diabetic patients: Effects on blood pressure and hormonal parameters. *Braz. J. Med. Biol. Res.* 35(8), 877-884.

- Rosenstock J**, Brown A, Fischer J, Thomas A, Nadeau D, Sussman A, Taylor T, Krol A, Magner J. (1998) Efficacy and Safety of Acarbose in Metformin-Treated Patients With Type 2 Diabetes. *Diabetes Care* 21, 2050-2055.
- Rosenstock J**, Sankoh S, List JF. (2008) Glucose-lowering activity of the dipeptidyl peptidase-4 inhibitor saxagliptin in drug-naive patients with type 2 diabetes. *Diabetes Obes Metab* 10, 376–386.
- Rowley MJ**, Mackay IR, Chen QY. (1992) Antibodies to glutamic acid decarboxylase discriminate major types of diabetes mellitus. *Diabetes* 41, 548-551.
- Rury RH**, Robert CT, Carole AC. (1999). A randomized double-blind trial of acarbose in type 2 diabetes shows improved glycaemic control over 3 years (U.K. Prospective Diabetes Study 44), *Diabetes Care* 22, 960–964.
- Rutten GEHM**, Verhoeven S, Heine RJ. (2000) Dutch College of General Practitioners.Guidelines on Type 2 Diabetes. *Huisarts en Wetenschap*, 42, 67-84.
- Sachiko H**, Hiroki I, Yukiko K, Yoshiharu W, Yoshiyuki H, Tomohisa A, Tetsuya K, Kazuhiro N and Hiroyuki K (2009) Efficacy and Safety of Miglitol:Switching Study from Voglibose in Japanese Patients with Type 2 Diabetes; *The Open Diabetes Journal*, 2, 60-61.
- Saely CH**, Aczel S, Marte T. (2004) Cardiovascular complications in type 2 diabetes mellitus depend on the coronary angiographic state rather than on the diabetes state. *Diabetologia* 47, 145 -146.
- Samreen Raiz**, (2009) Review Diabetes Mellitus, *Sci. Res. Assay* 4(5), 367-373.
- Santeusanio F**, Ventura MM, Contadini S. (1993) Efficacy and safety of two different dosages of acarbose in non-insulin dependent diabetic patients treated by diet alone. *Diabetes Nutr Metab* , 6, 147-154.
- Sartori C**, Trueb L, Nicod P, Scherrer U. (1999) Effects of sympathectomy and nitric oxide synthase inhibition on vascular action of insulin in humans. *Hypertention* 34, 586-589.
- Sato K**, Ozaki H, Salamon CM, Christopher RJ, Yamamoto M. (2008) Lack of dermal toxicity with the highly selective dipeptidyl peptidase-4 inhibitor alogliptin in monkeys (Abstract). *Diabetes* 57 (Suppl. 1): A5

- Saunier B**, Kilker RD Jr, Tkacz JS, Quaroni A, Herscovics A (1982) Inhibition of N-linked complex oligosaccharide formation by 1-deoxynojirimycin, an inhibitor of processing glucosidases. *J Biol Chem* 257, 14155–14161.
- Savona-Ventura C.** (2002) The History of Diabetes Mellitus A Maltese perspective. 4-6.
- Saydah SH**, Miret M, Sung J, Varas C, Gause D, Brancati FL. (2001) Postchallenge hyperglycemia and mortality in a national sample of US adults. *Diabetes Care* 24, 1397-1402.
- Scheen AJ**, Charpentier G, Ostgren CJ, Hellqvist A, Gause-Nilsson I. (2010) Efficacy and safety of saxagliptin in combination with metformin compared with sitagliptin in combination with metformin in adult patients with type 2 diabetes mellitus. *Diabetes Metab Res Rev* 26, 540–549.
- Schoonjans K**, Auwerx J. (2000) Thiazolidinediones: an update. *Lancet* 355, 1008-1010.
- Schweizer A**, Dejager S, Bosi E. (2009) Comparison of vildagliptin and metformin monotherapy in elderly patients with type 2 diabetes: a 24-week, double-blind, randomized trial. *Diabetes Obes Metab* 11, 804–812.
- Scott CR**, Smith JM, Cradock MM, Pihoker C. (1997) Characteristics of youth-onset noninsulin-dependent diabetes mellitus and insulin-dependent diabetes mellitus at diagnosis. *Pediatrics* 100, 84-91.
- Scott LJ**, Spencer CM. (2000) Miglitol: a review of its therapeutic potential in type 2 diabetes mellitus. *Drugs* 59, 521–549.
- Scott R**, Loeys T, Davies MJ, Engel SS. (2008) Efficacy and safety of sitagliptin when added to ongoing metformin therapy in patients with type 2 diabetes. *Diabetes Obes Metab* 10, 959–969.
- Scott RS**, Brown LJ. (1991) Prevalence and incidence of insulin-treated diabetes mellitus in adults in Canterbury, New Zealand. *Diabet Med* 8, 443-447.
- Segal P**, Feig PU, Schernthaner G, Ratzmann KP, Rybka J, Petzinna D, Berlin C, Dipl Math (1997) The Efficacy and Safety of Miglitol Therapy Compared With Glibenclamide in Patients With NIDDM Inadequately Controlled by Diet Alone, *Diabetes care* 20(5), 687-691.

- Segal P**, Feig PU, Scherthaner G, Ratzmann KP, Rybka J, Petzinna D, Berlin C (1997) The efficacy and safety of miglitol therapy compared with glibenclamide in patients with NIDDM inadequately controlled by diet alone. *Diabetes Care* 20, 687– 691.
- Seki M**, Tanaka T, Nawa H. (2004) Involvement of brain - derived neurotrophic factor in early retinal neuropathy of treptozotocin - induced diabetes in rats: therapeutic potential of brain - derived neurotrophic factors for opaminergic amacrine cells. *Diabetes* 53, 2412 - 2419
- Serra D**, He YL, Bullock J. (2008) Evaluation of pharmacokinetic and pharmacodynamic interaction between the dipeptidyl peptidase IV inhibitor vildagliptin, glyburide and pioglitazone in patients with Type 2 diabetes. *Int J Clin Pharmacol Ther* 46, 349–364.
- Shafiee G**, Mohajeri-Tehrani M, Pajouhi M and Larijani B. (2012) The importance of hypoglycemia in diabetic patients. *Journal of Diabetes & Metabolic Disorders* 11(17), 01-07.
- Shah SN**, Joshi SR, Parmar DV. (1997) History of Insulin. *J. Assoc. Physicians Ind* 45 (Suppl 1), 4-9.
- Shaw JE**, Sicree RA, Zimmet PZ (2010) Global estimates of the prevalence of diabetes for 2010 and 2030. *Diabetes Res. Clin. Pract.* 87,4-14.
- Shimabukuro M**, Higa N, Chinen I, Yamakawa K and Takasu N. (2006) Effects of a single administration of acarbose on postprandial glucose excursion and endothelial dysfunction in type 2 diabetic patients: a randomized crossover study, *J. Clin. Endocrinol. Metab.* 91, 837-842.
- Shosaku N**, Seitaro O, Takashi Y, Shinya F, Ryotaro O, Noritaka E, and Akira S. (2011) Effects of miglitol in platelet-derived microparticle, adiponectin, and selectin level in patients with type 2 diabetes mellitus. *Int J Gen Med.* 4, 539– 545.
- Shukla GD**, Bhela, Samhita, (1959) 6, 1-4.
- Shukla N**, Angelini GD, Jeremy JY. (2003) Homocysteine as a risk factor for nephropathy and retinopathy in type 2 diabetes. *Diabetologia* 46, 766-772.

- Siddiqui HH. (1993)** Safety of herbal drugs-an overview. *Drugs News & Views* 1(2), 7–10.
- Siddle K (1992)** *Insulin: Molecular Biology to Pathology*, eds. F. M. Ashcroft and S. J. Ashcroft, IRL Press, Oxford, 191.
- Soumya KV, N. Prem Kumara, Dharsanab JN, Seena KXC, Anjana AKD (2012)** Comparing the effect of antidiabetic activity of *andrographis paniculata*, *salacia reticulata* and *ocimum sanctum* by invitro screening. *Asian J Pharm Clin Res*, 5(4), 146-149.
- Stamler J, Vaccaro O, Neaton JD, Wentworth D (1993)** Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. *Diabetes Care* 16, 434-444.
- Standards of medical care in diabetes 2010. (2010)** *Diabetes Care*. Jan 33(Suppl 1), s11-s61.
- Sulkin T, Bosman D, Krentz AJ. (1997)** Contraindications to metformin therapy in patients with NIDDM. *Diabetes Care* 20, 925-928.
- Svensson M, Eriksson JW, Dahlquist G. (2004)** Early glycemc control, age at onset, and development of microvascula complications in childhood - onset type 1 diabetes: a population - based study in northern Sweden. *Diabetes Care* 27, 955-962.
- Tan CE, Emmanuel SC, Tan BY, Jacob E. (1992)** Prevalence of diabetes and ethnic differences in cardiovascular risk factors. The 1992 Singapore National Health Survey. *Diabetes Care* 22, 241-247.
- Tapp RJ, Tikellis G, Wong TY (2008)** Longitudunal association of glucose metabolism with retinopathy: result from the Australian Diabetes Obesity and Lifestyl (AusDiab) study. *Diabetes Care* 31, 1349-1354.
- Tetuo H, Am N, Takaharu K, Nobuyoshi O. (1984)** Effects of Acarbose, An a-glucosidase Inhibitor (bay g 5421), on Orally Loaded Glucose, Maltose and Sucrose and on Blood Glucose Control In non-insulin-dependent diabetics. *Nagoya J. Med. Sci.* 47, 35 - 41.

- The Oxford Centre for Diabetes**, Endocrinology and Metabolism: Diabetes Trials Unit. UK Prospective Diabetes Study [online]. Available from URL: <http://www.dtu.ox.ac.uk/ukpds/index.html> [Accessed 2008 Nov 23].
- Thomas L**, Eckhardt M, Langkopf E, Tadayyon M, Himmelsbach F, Mark M. (2008)(R)-8-(3-amino-piperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methylquinazolin-2-ylmethyl)-3,7-dihydro-purine-2,6-dione (BI 1356), a novel xanthine-based dipeptidyl peptidase 4 inhibitor, has a superior potency and longer duration of action compared with other dipeptidyl peptidase-4 inhibitors. *J Pharmacol Exp Ther* 325, 175–182.
- Tissera MHA**, Thabrew MI (2001) Medicinal plants and Ayurvedic preparations used in Sri Lanka for the control of diabetes mellitus. A publication of the Department of Ayurveda, Ministry of Health and Indigenous Medicine, Sri Lanka.
- Tripathi BK**, Srivastava AK. (2006) Diabetes mellitus: Complications and therapeutics; *Med Sci Monit* 12(7), 130-147.
- Tuomilehto J**, Zimmet P, Mackay IR. (1994) Antibodies to glutamic acid decarboxylase as predictors of insulin-dependent diabetes mellitus before clinical onset of disease. *Lancet* 343, 1383-1385.
- Turnbull FM**, Abairra C, Anderson RJ, Byington RP, Chalmers JP, Duckworth WC (2009) Intensive glucose control and macrovascular outcomes in type 2 diabetes. *Diabetologia*, Erratum 52(2470), 2288–2298.
- U.S. Patent No. 4,639,436**, NDA 20-682/S-008, Glyset miglitol tablets, product information.
- UK Prospective Diabetes Study (UKPDS) Group (1998)(A)**. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS33). *Lancet* (352): 837-853.
- UK Prospective Diabetes Study Group (1998) (B)**. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). *Lancet*(352),854-865.

- Upadhyay OP**, Upadhyay DO, (1987) A few facts of historical interest relating to Diabetes Mellitus 22(3), 235-239.
- Van de Laar FA**, Lucassen PL, Akkermans RP, Van de Lisdonk EH, Rutten GE, Van Weel C. (2005) Alpha-glucosidase inhibitors for type 2 diabetes mellitus. Cochrane Database Syst Rev 2, CD003639.
- Venkatesh S**, Reddy GD, Reddy BM, Ramesh M, Appa Rao AVN (2003) Antihyperglycemic activity of *Caralluma attenuata*. *Fitoterapia* 74, 274-279.
- Villhauer EB**, Brinkman JA, Naderi GB. (2003) 1-[[[(3-hydroxy-1-adamantyl)amino]acetyl]-2-cyano-(S)-pyrrolidine: a potent, selective, and orally bioavailable dipeptidyl peptidase IV inhibitor with antihyperglycemic properties. *J Med Chem* 46, 2774–2789.
- Vincent SH**, Reed JR, Bergman AJ. (2007) Metabolism and excretion of the dipeptidyl peptidase 4 inhibitor [14C]sitagliptin in humans. *Drug Metab Dispos* 35, 533–538.
- Vinik A.** (1999) Diabetic Neuropathy Pathogenesis and Therapy. *Am J Med* 107(2B), s17-s26.
- Vinik AI**, Park TS, Stansberry KB, Pittenger GL (2000) Diabetic neuropathies. *Diabetologia* 43, 957-973.
- Wascher T**, Schmoelzer I, Wiegratz A, Stuehlinger M, Mueller-Wieland D, Kotzka J, Enderle M (2005) Reduction of postchallenge hyperglycaemia prevents acute endothelial dysfunction in subjects with impaired glucose tolerance. *Eur J Clin Invest* 35, 551-557.
- Williams JA**, Choe YS, Noss MJ, Baumgartner CJ, Mustad VA. (2007) Extract of *Salacia oblonga* lowers acute glycemia in patients with type 2 diabetes *Am J Clin Nutr.* 86(1), 124-130.
- Williams-Herman D**, Engel SS. (2010) Safety and tolerability of sitagliptin in clinical studies: a pooled analysis of data from 10,246 patients with type 2 diabetes. *BMC Endocr Disord* 10-17.
- Willis J**, Scott R, Brown L. (1998) Type 1 diabetes in insulin-treated adult-onset diabetic subjects. *Diabetes Res Clin Pract* 42, 49-53.

- William JA**, Choe YS, Noss MJ, Baumgartner CJ and Mustad VA. (2007) Extract of *Salacia oblonga* lowers acute glycemia patients with type – 2 diabetes. Am. J. Cli. Nutr 86 (1), 124-130.
- Winder WW**, Hardie DG. (1999) AMP-activated protein kinase, a metabolic master switch: possible roles in type 2 diabetes. Am J Physiol 277, E1-E10.
- Wing RR**, Tate DF, Gorin AA, Raynor HA, Fava JL. (2006) A self-regulation program for maintenance of weight loss. N Engl J Med 355, 1563–1571.
- Wolf BW**, Weisebrobe SE. (2007) Food Chem, Toxicol 41, 867 – 874.
- World Health Organization**. Fact Sheet No.312: (2009) What is Diabetes? Available at: <Http:// www.who.iny/mediacentre/factsheets/fs312/en/> Accessed on: September 5.
- World Health Organization**. (1980)Second report of the WHO expert committee on diabetes mellitus. Technical report series no. 646. Geneva, Switzerland.
- Yang W**, Lu J, Weng J, Jia W, Ji L, Xiao J, Shan Z, Liu J, Tian H, Ji Q, Zhu D, Ge J, Lin L, Chen L, Guo X, Zhao Z, Li Q, Zhou Z, Shan G, He J. (2010) Prevalence of diabetes among men and women in China. N Engl J Med 362, 1090-1101.
- Yki-J arvinen H**. (2004) Thiazolidinedions. N Engl J Med 351, 1106-1118.
- Yki-Ja’rvinen H**. (2001) Combination therapies with insulin in type 2 diabetes. Diabetes Care 24, 758-767.
- Yoshikawa M**, Murkami T, Yashira K, Matsyuda H. (1998) Kotalanol, a potent alpha glucosidase inhibitor with thiosugar sulfonium sulfate structure from antidiabetic ayurvedic medicine *Salacia reticulata*. Chemical and Pharmaceutical Bulletin 46, 1339–1340.
- Yoshikawa M**, Murkamy T, Yashiro K and Matsu-da H Kotalanol. (1998) A potent alpha gluco-sidase inhibitor with thiosugar sulfonium sulphate structure from antidiabetic Ayurvedic medicine *Salacia reticulata*. Chem and Pharm Bull 46, 1339-1340.
- Yoshikawa M**, Ninomiya K, Shimoda H, Nishida N. and Mastuda H. (2002) Hepatoprotective and antioxidative property of *Salacia reticulata*; preventive effects of phenolic constituents on CCl₄ induced Liver injury in Mice. Biol. Pharma. Bull. 25(1), 72-76.

- Yoshikawa M**, Nishida N, Shimoda H and Takada M. (2001) Polyphenol constituents from *Salacia* species: quantitative analysis of mangiferin with alpha-glucosidase and aldose reductase inhibitory activities. *Yakugaku Zasshi* 121(5), 371-378.
- Yoshikawa M**, Shimoda H, Nishida N, Takada M and Matsuda H (2002) *Salacia reticulata* and its polyphenolic constituents with lipase inhibitory and lipolytic activities have mild antiobesity effects in rats. *J Nutr.*132, 1819–1824.
- Yoshikawa M**, Shimoda H, Nishida N, Takada N, Mastuda H. (2002) *Salacia reticulata* and its phenolic constituents with Lipase Inhibitory and Lypolytic Activities have mild antiobesity effects in rats. *J. Nutr.* 132, 1819 -1824,.
- Yoshino K**, Miyauchi Y, Kanetaka T, Takagi Y and Koga K (2009) Anti diabetic activity of a leaf extract prepared from *Salacia reticulata* in mice. *Biosci. Biotechnol. Biochem.* 73(5), 1096-1104.
- Yuichi S**, Ikuo I, Takanari N, Makoto S, Masatoshi S, Sei-ichi G, Takuya A, Tsugikazu K, Shigehiro K. (2006) Acarbose improves fibrinolytic activity in patients with impaired glucose tolerance *Metabolism Clinical and Experimental* 55, 935–939.
- Zamani M**, Cassiman JJ. (1998) Reevaluation of the importance of polymorphic HLA class II alleles and amino acids in the susceptibility of individuals of different populations to type I diabetes. *Am J Med Genet* 76, 183-194.
- Zhou G**, Myers R, Li Y. (2001) Role of AMP-activated protein kinase in the mechanism of action of metformin. *J Clin Invest* 108, 1167-1174.